POSTED: Oct. 5, 2012

In this 13-minute interview, Dr. Antoni Ribas of UCLA's Jonsson Comprehensive Cancer Center provides an extesnive overview of the latest positive advancements in the use of combined BRAF and MEK inhibitors to treat metastic melanoma. These latest findings provide strong support for testing the combination therapy in future human clinical trials, which Jonsson Cancer Center researchers hope to launch within two years.